Amicus Therapeutics, Inc. (NASDAQ:FOLD) closed its last session at $6.94 with the change of +2.36%. The market capitalization of the company is $986.44M with an average Volume of 2.23 million shares. The stock currently has its 52-Week High range of $18.09 and 52-week low range of $4.98. The Price to Book (P/B) ratio stands at 2.73. The stock traded total quantity of 1.33 million shares.
Currently Amicus Therapeutics, Inc. (FOLD) captured an average recommendation of “ Overweight ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “6″ Analysts”. “0” rated “Sell” for the company. “2” said the company as a “Hold”. Overweight rating was given by “0” and Underweight rating was given by “0”.
Analysts are expecting that the company to achieve $12.75 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $19.00 however minimum price target advised by analysts is $9.00. The Median price target for the stock is measured at $12.50.
Presently, Analysts decided consensus EPS estimate of $-0.31 for present quarter and one month ago projected EPS estimate was at $-0.31. If we take a look at back 3 month ago, consensus EPS estimate was $-0.33.
A current consensus EPS estimate for next quarter is at $-0.29 and 3 month ago EPS forecast was $-0.35. Have a look at back 1 month ago, consensus EPS forecast was seen at $-0.29.
For current fiscal year, most recent EPS estimate is set at $-1.35 based on Analyst consensus and three month ago consensus EPS opinions was at $-1.35. During period one month ago, consensus EPS forecast was decided at $-1.32.
A current consensus EPS projection for next fiscal year is observed at $-1.00 and one month ago consensus EPS forecast was at $-0.99. Take a look at back three month ago, consensus EPS estimate opinions was decided at $-1.08 by analysts.
One Month ago, the stock has gained consensus mean rating of Overweight based on the analysis of brokerage analyst firms polled. 6 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 0. 2 advised the “Hold” rating about this stock. 0 revealed “Sell” signal and “Underweight” rating was declared by 0.
Three Months Ago, Analysts recommended an average brokerage rating of Overweight derived from brokerage firms, according to FactSet. 6 said a “Buy Rating” and 0 announced “Overweight Rating”. 2 advised “Hold Rating” regarding the stock. 0 announced “Sell Rating” and 0 disclosed “Underweight Rating”.